Phathom Pharmaceuticals (PHAT) Accounts Payables (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Accounts Payables data on file, last reported at $6.4 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $6.4 million, down 45.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (down 45.21% YoY), and the FY2025 annual result was $5.0 million, down 52.57% from the prior year.
• Accounts Payables grew to $6.4 million in Q1 2026 per PHAT's latest filing, from $5.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $12.6 million in Q4 2023 and troughed at $1.1 million in Q3 2025.
• A 5-year average of $6.8 million and a median of $6.4 million in 2026 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables soared 94.12% in 2022, then tumbled 84.93% in 2025.
• A 5-year view of Accounts Payables shows it stood at $10.0 million in 2022, then rose by 26.05% to $12.6 million in 2023, then declined by 16.62% to $10.5 million in 2024, then tumbled by 52.57% to $5.0 million in 2025, then grew by 27.73% to $6.4 million in 2026.
• Business Quant data shows PHAT's Accounts Payables at $6.4 million in Q1 2026, $5.0 million in Q4 2025, and $1.1 million in Q3 2025.